the operational restriction XXXX to COVID QX. continue experiencing in the improving the presentation, had of create significantly. some COVID were health Then chain in and we'll will in and download the latest also care regulatory chain earnings how earnings hit Good are morning, rose growth the efficiency results. capabilities. the severely and will report logistics Chen strengthening What the building increased QX on in encourage rising earlier you Mr. tremendous our areas. and for also zero momentum, in add disrupted at China good I Luke policies business development challenges More posted infected today's today and ir.XXX.com.cn. epidemic financial The the that the I'll I some with latest company's cover and opportunities. in cities strategies cities company you call. our development color the the industry walk to our our to supply policies you In of the evening. challenges discussing transportation joining to people call, numbers slides and here Thank number lockdown along be general website. for consequently, in supply and to is tightly more was of and regulated through other provided
in was to to time. our in needed literally with out challenges, challenge our biggest customers they Our team proud that dealing the truly stock and medicine stood report unprecedented mountains the for to those to have I'm badly move goods fulfill and customers patients. deliver replenished to our
and consultation highly patients' medical spared Our offline with epidemic to in online meeting proved We dealing digital pandemic. the in cities drugs. hit be effective no demand and in platform efforts for
hotels rising but our you due be able we control online few and to to online products is fleet over of provided near some disruptive have pandemic. to for as different also infected facilities. the number hit the team few very very create future, Since believe for right of hospitals, few provinces products in of The government lockdown logistic us fleet with drugs we the mobile have to have services. and challenges overcome is cities utmost regulatory A continue our which the fulfillment consultations free more challenges COVID-XX COVID-XX in other had a We will believe approved in to by beginning approval, with faith the our covering latest a for followed. to patients few developments. offering strong take dedicated policies in to cross-provincial medical weeks consultation provinces provided online the We moment lockdown field XXX and customers deliver our delivery staying me medical Even the last in are quarantine months. allow a in last we provided now, done has centers X,XXX in to a I under to sharply free the pandemic, business. saw Please and XXX the over people X quarters. diseases customers few than our effort last Clinic been Recently, that medicinal serve quite will hospital brief to the
As you XXth communist October. its Congress party the just National of know, finished in China
efficacy One of us early National health there stressed XXth from focus of to more technologies launch key its opportunities early disease role treatment. management, from screening, and TCM recent disease management. Chinese can and of and the government strengthening infectious for diseases major remarks China's mean of chronic the VBP, better promote very the price includes remarks. Party types less drugs management for direction relatively Opening health will years, and improving Rx in themes Two, the with areas to policies, had the mention Three, is has preliminary disease made to on of is health following a The have to XXX mental government global drugs of over construction China, This as of TCM better for and efforts practicing will of China the on TCM. domestic chronic and supportive digital Significant great in a platform. to innovation the granules, standardization new revitalizing to commercialize where which innovation. containment run diagnosis, prices initiative few newer was been strategic control of supportive many not disease digital to the diseases. The may the drugs. and increase also a The sharply, should encouraging including healthy important the drop modernization plenty create heading pickup hub chronic disease In tailwinds an treatment chronic bring rehabilitation as anticipate of youth market and more capabilities cut its the and regulatory we allow in industry. world. managements integrated or sales space government routine industry government funding environment play the TCM. therapies act China having the The in disease enhancing treatment pledged Congress be to of and drugs prevention, and an market with policy preventative, already the in control is Four, for focusing our infectious the innovation other a which set safety infrastructure elderly as effect early improve issued be boosting provided care. of have will as care increases. intention encouraging of priority compared penetration TCM and and initiatives on a has where a that innovation will a years. gradual provide broad in to the diseases. infectious Medicine. The next and Traditional in Importance One, seen We
deductions, rate in Xth the child row falling such rate policy, in the tax maternity government for policies longer third to the XXXX, a as implemented year the birth the birth With for are financial and to insurance, leave, that our enhanced products children. private child. I'm the subsidies medical third additional housing infants targeting support some report and happy of the label specifically boost
and elderly. for use broaden should a range have our portfolio, we products of we As
under In which the prevention and addition, control State further public announced implement will COVID-XX China roll out measures to for Council and precise, epidemic measures reasonable the XX response, efficient and needs. optimize control
provinces cities the approaches various announced taking and even there have this Although as measures place, different a days, we it's control and from obvious in early positive and very see are been implementation deviation move.
decreasing [ph] coating Omicron measures. media adjustment of containment stage China's indicates new the officials the saw vaccination senior control increasing of and toxicity potentially outbreak the the mission. we pandemic of yesterday, faces prevention, an fact, accumulating COVID and current that the rate experience This variant, and with In
was Despite in capital to the its the has districts. against fight forward growth the pandemic when economic COVID-XX measures the offline We the that the downturn look usual. cities, margin. behind development on and containment material revenue new gross we the in impact welcome the much a time third in yesterday very One the of of designation solid saying all and major moderate and and pandemic is adverse in XX in as to extent the Guangzhou varying managed China risk general business levels growth adjusted in city can quarter, sector a operate where retail
while billion, X.X% profit net year-over-year. to segment revenue third XX% increased X.X Our by increased year-over-year for our gross by quarter RMB
profile deliver margin the our continued improve efforts Our results during to positive quarter. to
to of same segment a improved gross as margin quarter the overall X% in from percentage Our revenues year. of X% last net
hard-burnt an circumstances, growth product the margin technical this optimized quite as came efficiency capabilities. achievement the improved well pricing, assortment smart Given team as and from accomplishment. is and This
revenue of margin business of BXB reached RMB Gross key billion. BXB X.X% last X.X% year. increase our improved year-over-year. contributor quarter the XX% from our million, RMB to of to of growth, the which BXB Our segment rose remains profit X.XX segment XXX in same an
last We the also XX.X% XX.X% quarter improved in the to year. margin same BXC segment from
value-added leverage offerings. assortment and capabilities our to services service our well our partners. demand able market reducing to will more product costs We were procurement continues as continue show as diverse deliver our optimizing to for We strong digital The to structure.
supply consultation, the patient same RMB XX% vendor during Our representing commercialization include a of the value-added services, growth marketplace million, services over drug medical of our service management, year. education, e-prescription last quarter cetera. online digital revenue services, reached tools, Even et XX.XX pandemic, chain marketing,
as and partner, offer and to as companies. value-added commercialization an services continue to pharmaceutical position continues to we business our pharmacies As ourselves effective we will expand
X.X% Sales result, same this In addition, X.X% down were were quarter revenues and efficiency. net percentage last as and expenses X.X% to were total of operational same and we marketing our expenses from XX.X% to from a in to X.X% expenses quarter the from General X.X% decreased technology to X.X%. from last in the X.X% operating as to continued quarter in And down year. a administrative expenses year. enhance down
We focus services our to customers. to expect superior as on to we continue while delivering momentum we this continue scale
continue still the the to to report that our Although black narrowed revenues milestone that our quarter, to environment of closer in operating to to of which our macroeconomic loss grow and in our pleased to I'm overall the gross operations flow We're net our committed we're executing our X.X% resulted to see compared also were quarter in the getting cash business. profitability. major last for a cash We're same year. and and is flow to strategy closer from X.X% pleased current revenue non-GAAP business, margin. was challenges as has to
QX of XXX's XX% more of As network than China. pharmacies, covering approximately pharmacy of virtual XXX,XXX XXXX, in total [ph] the number reached pharmacies
pharmaceutical progress The [ph] companies this initiative. X.X% profit. we over overall revenue to This platinum our of particular. present our orders carried become contributed program. quarter made high-margin deployed of XX% complete BXB can which continuously out cold-chain XX profit, In label service more provided to consumers BXB increase private X,XXX has a by has on As update program. of September, gross gross over capability convenience than have pleased the XXX the XXX has and for XX% in I'm improve to SKUs over cities, rural this have part order year-on-year and within of have we At in hours. increased in product products
well. As label with their of supplements, our products. build this some pharmacy suite manufacturers some it's helps our Not products, include to which help with and a own continues network pharmaceutical devices, grow should our et margin, medical will pharmacies We private cetera. customers improve this only medicines, gross health but as introduce we time of partnered margin to to
three So and already far, brands, launched schedule, targeting or XX production over we segments. are SKUs [indiscernible] developed already have in specific market which
yet, will Although believe products at significantly profit business of our conclusions customer this stage downstream these proprietary infant still and increase enhance the can its we part drawn stickiness. gross is be and no
we companies, commercialization efforts. drug them pharmaceutical their upstream efficiency able and to with to help relationship marketing digital our were deepen we As improve
life in cycle participated the leveraging now for post-diagnosis successfully Now for medicine, oral couple let We the plus teenagers. actively which which offline examples. refuel [ph] only full offer we disease our patient consultation consultation Since platform, management services [indiscernible] and approved a launch China clinical launch drug of for in completed me abroad and online covering innovative trials effectively China in by a and the help the provide of control progression. is of closed-loop patients [indiscernible] atomic Atopic China's recent and targeted dermatitis service, its drug, drug,
profile compliance In reduce rates. addition, we'll help patients improve effectively [ph] medication and
to professionals in caring We full-time manner. also provided a respond timely questions patients' online to medical
of national glucokinase Also rolled type span have China, Within diabetes [ph] Medicine patients served dorzagliatin activator November, With the the medicine drug we provinces. in of out new partner rollout one were channels. drug, smart our providing platform, in the a across digital patients capabilities Hua in all with and in supply our the chain XX launch in of month, in its strategic a X assist advantages to its treatment a leveraging first-in-class option. able we
scrambling so through more The Hua We increase thus accessibility to life patients manufacturing convenience with that shortage. inventory launch was and reservation to cope of the have drug cycle the enhanced registration professionals by supply is providing the a new also successful so was with capacity Medicine to medical depleted treatments. therapeutic full that management, fast of its new patient access
broad will to pharmacies. the care opportunities order business model of in country's in health gap In strategic plan given Looking of the of pursue connect via network on population strengthening BXC millions cities every we in will opportunity lower-tier and focus expedite enormous transformation market facet digital mass to the access, us platform bridge of continue SXBXC our consumer our people we direct with to China, ahead, the our advancing the and which market from expansion. provides our to
greater [ph] predictive our the power higher and keep handle AI with side, improving technology, we'll the volumes On asking processing ability. data capability to infrastructure of its
platform's pharmacies we cost of will platform Our and to can network of deepen XX,XXX will and connect the access a result we also fast and the growth commercializing. those better to will today our customers. believe same control able virtually to sales retail us digital for at of allow drive sales and this commercialize time, of enhanced grow their pharmacy pace existing which share be SKUs the SKUs future. over pharmacy retail customers. modules at wallet in The upstream will margins pharmacies store our of the data With further efficiency point are in and features for We technology the and more provide pharmacies this, among near more sales number greater suppliers will deploy capability
an commercialization selection health-related us allowing pharmaceutical efforts deepen companies the in provide of On with even we supply our wider side, of and support the relationships services to help them their medications to for innovations for a also our pharmacy an China, customers Globally benefit products happening unprecedented a at and been in This medical consumers. and commercialization services rate. represents major us. have growth in opportunity source
a As increasingly can XXX's more the online to company's during is Ultimately, devices come for all. increase our launch our likelihood our and win-win market competition product new position medications market, platform on intense. more the offline and launch. support becomes of successful and and improve a integrated
in Internet health the to expedite the care us system for digital are there of the opportunities transform believe of care to China. age transformation in for help the we As health that better, significant we system industrial
strengthen will our strengthening this opportunities operational continuing service We cost be post priorities broadening network reduced Operationally, growth efficiency, and our and fulfillment offerings. and margin to relentlessly pursue revenue to optimizing model costs, delivering supply procurement work growth, will improve and COVID-XX.
now in have come of a care ago, have industry. XXXX. the in From major block since IPO kid the the a established we X years our health one We as new long service way in players ourselves digital
a for chain continue drug to uniquely in positioned digital with pharmacies the to E-commerce value by awarded of enterprise network, were Ministry broadening our National infrastructure, create We supplier's chain. High-tech was the Commerce. we're Science and prize by the capabilities our we partners of certified expand the As Ministry Enterprise of Technology recently National again. and value Demonstration also all the plus as coverage advanced Chinese supply XXX of our China
along. and economic very we and digital are [ph] and through and thank a to refill supported solutions for been Moreover, Area, Our in the in Chen received to hydatid online from results. financial will hospital Shanghai earned distinction have platform continuous All study New hospital values, and and we selected who control. our disease efforts local implementation. past. social in Thank I Science us the governments, now continued the City innovation for all hand Gansu ESG a Sichuan production critical patients our support prescription Pudong services We firmly has committed walk carry We're disease Technology remote consultation have resumption the living you. all for call Tibetans us have chronic core by our proud to service will Mr. for we Commission. and done as province wish that efforts our have and specialists to case also investors our such Luke control claim fulfill the as responsibilities
